Q4 Earnings Estimate for SRPT Issued By William Blair

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Stock analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a report issued on Monday, January 27th. William Blair analyst S. Corwin anticipates that the biotechnology company will post earnings of $3.60 per share for the quarter. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.49 per share.

SRPT has been the subject of several other reports. Evercore ISI decreased their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. Robert W. Baird lowered their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research report on Thursday, November 7th. StockNews.com cut Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a report on Monday, October 21st. They issued a "buy" rating and a $165.00 target price on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and set a $202.00 price target on shares of Sarepta Therapeutics in a report on Monday, January 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $178.71.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock traded up $0.16 during trading hours on Thursday, reaching $113.88. 221,321 shares of the company were exchanged, compared to its average volume of 819,644. Sarepta Therapeutics has a 12 month low of $102.15 and a 12 month high of $173.25. The firm has a market cap of $10.88 billion, a price-to-earnings ratio of 91.10 and a beta of 0.75. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a 50-day moving average of $122.80 and a 200 day moving average of $126.94.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Manchester Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after buying an additional 156 shares during the last quarter. Sunbelt Securities Inc. boosted its stake in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 232 shares during the period. Huntington National Bank increased its holdings in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new stake in Sarepta Therapeutics in the 4th quarter valued at $36,000. 86.68% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Kathryn Jean Boor sold 1,636 shares of the company's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company's stock, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.